The treatment of metabolic disorders, particularly diabetes, represents one of the earliest and most successful applications of peptide therapeutics. Insulin itself is a peptide hormone ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists as part of a regular treatment regimen. If you’re living with diabetes, you can greatly reduce your risk for cardiovascular ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Bengaluru: Biocon Limited, a global biopharmaceutical company, has announced that the company has received approval in India ...

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC ...